Stenocare A/S has entered into a new partnership agreement with Quest Biotech Pharma ("QBP"), aimed at expanding its reach to more prescribing doctors and patients in Australia. The agreement has the potential to double the sales run rate of Stenocare-branded products in Australia during 2024. Partnering for patient reach.

Under a new agreement, Stenocare has partnered with Quest Biotech Pharma ("QBP"), a highly specialized Australian pharmaceutical company. QBP is able to significantly increase the capacity of prescribing doctors of Stenocare branded products via multiple channels. The shared objective is to expand the reach to more patients through qualified prescribing doctors.

QBP partners with an holistic tele healthcare clinic - TeleDocs Clinic - serving patients with convenient access to medical care services nationwide from the Eastern States to Western Australia. This is a vast area with services open to all of Australia's 26.6 million population. The mutual goal is to capture market share and achieve a 100% growth in the sales run rate of Stenocare-branded products in 2024.